Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor

Arthritis and Rheumatism

Volumn 63, Issue 4, 2011, Pages 894-903

  Todd, Derrick J ^a,b   Knowlton, Nicholas ^b   Amato, Michael ^a,b   Frank, Mark Barton ^b   Schur, Peter H ^a,b   Izmailova, Elena S ^c   Roubenoff, Ronenn ^d,e,f   Shadick, Nancy A ^a,b   Weinblatt, Michael E ^a,b   Centola, Michael ^b   Lee, David M ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e BIOGEN   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; GAMMA INTERFERON; GELATINASE B; HETEROPHILE ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RHEUMATOID FACTOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ERROR; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS;

ANTIBODIES, HETEROPHILE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHEMOKINES; CYTOKINES; DIAGNOSTIC ERRORS; HUMANS; IMMUNOASSAY; PROTEIN BINDING; RHEUMATOID FACTOR;

EID: 79953676591     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30213     Document Type: Article

References (33)

1. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66 Suppl 3:iii2-22.
2. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66:712-9. (Pubitemid 46846688)
3. Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010;62:383-91.
4. Jorgensen KT, Wiik A, Pedersen M, Hedegaard CJ, Vestergaard BF, Gislefoss RE, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008;67:860-6. (Pubitemid 351829389)
5. Khan IH, Krishnan VV, Ziman M, Janatpour K, Wun T, Luciw PA, et al. A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom 2009;76:159-68.
6. Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol 2007;25:584-92. (Pubitemid 47484592)
7. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010;42: 508-14.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Dorner RW, Alexander RL Jr, Moore TL. Rheumatoid factors. Clin Chim Acta 1987;167:1-21. (Pubitemid 17147604)
10. Sawilowsky SS. Review of the rank transform in designed experiments. Percept Mot Skills 2000;90:489-97.
11. Gaddis GM, Gaddis ML. Introduction to biostatistics: part 5, statistical inference techniques for hypothesis testing with nonparametric data. Ann Emerg Med 1990;19:1054-9. (Pubitemid 20275256)
12. Kato K, Umeda U, Suzuki F, Hayashi D, Kosaka A. Use of antibody Fab- fragments to remove interference by rheumatoid factors with the enzyme-linked sandwich immunoassay. FEBS Lett 1979;102:253-6. (Pubitemid 9221718)
13. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999;45:942-56. (Pubitemid 29340529)
14. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000;235:71-80. (Pubitemid 30089785)
15. De Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005;300:124-35. (Pubitemid 40805593)
16. De Jager W, Rijkers GT. Solid-phase and bead-based cytokine immunoassay: a comparison. Methods 2006;38:294-303.
17. Alshekaili J, Li C, Cook MC. Heterophile interference accounts for method-specific dsDNA antibodies in patients receiving anti-TNF treatment. Rheumatology (Oxford) 2010;49:891-7.
18. Toedter G, Hayden K, Wagner C, Brodmerkel C. Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin Vaccine Immunol 2008;15:42-8. (Pubitemid 351966532)
19. Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008;153:188-95. (Pubitemid 351989164)
20. Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009;11:R76.
21. Fabre S, Guisset C, Tatem L, Dossat N, Dupuy AM, Cohen JD, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009;155:395-402.
22. Vis M, Bos WH, Wolbink G, Voskuyl AE, Twisk JW, Van de Stadt R, et al. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. J Rheumatol 2008;35:425-8. (Pubitemid 351374415)
23. De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:299-302. (Pubitemid 40193631)
24. Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieude P, Grootenboer-Mignot S, et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009;76:248-53.
25. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54. (Pubitemid 36959194)
26. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098-107.
27. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491.
28. Szodoray P, Alex P, Brun JG, Centola M, Jonsson R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004;59:592-9. (Pubitemid 38789229)
29. Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, et al. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005;117:168-76. (Pubitemid 41407727)
30. Kishida Y, Haruna Y, Naitoh M, Katayama K, Kashiwagi T. Multiple cytokine profiling of the therapeutic responses to ribavirin and pegylated interferon-α2b using an "induction" approach with natural interferon-β in difficult-to-treat chronic hepatitis C. J Interferon Cytokine Res 2009;29:353-68.
31. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009;83:3719-33.
32. Fournier PE, Thuny F, Richet H, Lepidi H, Casalta JP, Arzouni JP, et al. Comprehensive diagnostic strategy for blood culturenegative endocarditis: a prospective study of 819 new cases. Clin Infect Dis 2010;51:131-40.
33. Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986;32:1491-5. (Pubitemid 17027766)